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Background: The prevalence of overweight and obesity is increasing globally and is an established risk 2 
factor for cardiovascular disease (CVD). Our objective was to evaluate the impact of overweight and 3 
obesity on life expectancy and years lived with and without CVD in older adults. 4 
Methods: The study included 6636 individuals (3750 women) aged 55 years and older from the 5 
population-based Rotterdam Study. We developed multistate life tables by using prevalence, incidence 6 
rate and hazard ratios (HR) for 3 transitions (free-of-CVD-to-CVD, free-of-CVD-to-death, and CVD-to-7 
death), stratifying by the categories of body mass index (BMI) at baseline and adjusting for confounders.  8 
Results: During 12 years of follow-up, we observed 1035 incident CVD events and 1902 overall deaths. 9 
Obesity was associated with an increased risk of CVD among men (HR 1.57 (95% confidence interval 10 
(CI) 1.17, 2.11)) and women (HR 1.49 (95%CI 1.19, 1.86)), compared with normal weight individuals. 11 
Overweight and obesity were not associated with mortality in men and women without CVD. Among men 12 
with CVD, obesity compared to normal weight, was associated with a lower risk of mortality (HR 0.67 13 
(95%CI 0.49, 0.90)). Overweight and obesity did not influence total life expectancy. However, obesity was 14 
associated with 2.6 fewer years (95%CI -4.8, -0.4) lived free from CVD in men and 1.9 (95%CI -3.3, -0.9) 15 
in women. Moreover, men and women with obesity lived 2.9 (95%CI 1.1, 4.8) and 1.7 (95%CI 0.6, 2.8) 16 
more years suffering from CVD compared to normal weight counterparts.  17 
Conclusions: Obesity had no effect on total life expectancy in older individuals, but increased the risk of 18 
having CVD earlier in life and consequently extended the number of years lived with CVD. Due to 19 
increasing prevalence of obesity and improved treatment of CVD, we might expect more individuals living 20 
with CVD and for a longer period of time.  21 




Obesity is increasing globally and the association between body weight, morbidity and mortality has 23 
received widespread attention.
1
 There is consensus on the association of overweight and obesity with 24 
mortality in young adults and middle-aged,
2
 but there is no clear consensus for the elderly.
3-5
 Several 25 
studies have reported that among older individuals the longest survival is observed in the overweight and 26 
obese range.
5-7
 However, older individuals with obesity are still at higher risk to develop cardiovascular 27 
disease (CVD) in their remaining lifespan.
8
  Therefore, the contribution of obesity to life expectancy and in 28 
particular life expectancy with and without CVD among older individuals is still of relevance.  29 
Previous studies investigating the impact of overweight and obesity with total life expectancy have 30 
reported that obesity in adulthood is associated with a decrease in total life expectancy of 6-7 years, and 31 
severe obesity in men aged 20 to 30 will shorten life expectancy by 13 years, compared with normal 32 
weight individuals.
9, 10
 Another study evaluating the association of obesity at the age of 45 years with total 33 
life expectancy and life expectancy with and without CVD has shown that obesity not only reduces total 34 
life expectancy, but also reduces the number of years lived free of CVD by 6.0 years in men and 8.4 in 35 
women.
11
 However, most of studies described have evaluated the effect among young adults, while the 36 
effect of obesity on survival in the elderly remains controversial.
3, 5
 Furthermore, these studies have used 37 
data from the Framingham Heart Study using information collected during the second half of the 20
th
 38 
century. In recent decades, an increase of obesity prevalence
12
 has been observed along with 39 
improvements in prevention and treatment of CVD.
13
  40 
Therefore, in a population-based study of subjects 55 years and older, we aimed to evaluate the impact of 41 
overweight and obesity in the average years lived with and without CVD. We constructed multistate life 42 
tables using data collected from 1997 and with over 12 years of follow up from the Rotterdam Study.  43 




Study population 45 
This study was embedded within the Rotterdam Study, a prospective population-based cohort study 46 
among adults and elderly living in the Ommoord district of Rotterdam, The Netherlands. The baseline 47 
examination was completed between 1990 and 1993 by trained research assistants for 7983 participants 48 
(RS-I). In 2000–2001, the Rotterdam Study was extended with 3011 participants who had become ≥55 49 
years of age or had moved into the study district (RS-II). The objectives and design of the Rotterdam 50 
Study have been described in detail elsewhere.
14
 51 
For the current study, we used data from the participants attending the third examination of the original 52 
cohort (RS-I-visit 3, 1997–1999; n=4797) and the participants attending the first examination of the 53 
extended cohort (RS-II-visit 1, 2000–2001; n=3011).   54 
We excluded participants who did not visit the research center, did not have information on body mass 55 
index (BMI) (n=1051, the baseline characteristics of this subgroup are presented in Table 1 in the 56 
supplementary material), or no information on smoking behavior (n=40). Additionally, we excluded 57 
participants who had BMI ≤ 18.5 (n=51) to account for disease-related weight loss. Finally, we excluded 58 
participants without written informed consent (n=30). After exclusion, 6636 participants (3750 women) 59 
were available for the current analysis. All participants provided written informed consent to participate in 60 
the study and to obtain information from their treating physicians.  61 
Assessment of anthropometric measurements, health behaviors and laboratory measurements 62 
Anthropometrics were measured in the research center by trained staff. Height and weight were 63 
measured with the participants standing without shoes and heavy outer garments. We calculated BMI by 64 




 According to the WHO cut-off criteria, we composed BMI as 65 
a categorical variable with three categories: normal weight (18.5≤ BMI<25), overweight (25≤BMI<30) and 66 
obese (30≤BMI).
15
 Smoking status was categorized as current smoker, former smoker and never smoker, 67 
and additionally we accounted for cigarettes smoked per day. Information on education was assessed 68 
according to the standard international classification of education and was composed into four categories: 69 
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elementary education, lower secondary education, higher secondary education, and tertiary education.
16
 70 
Marital status was divided in single, married, widowed or divorced/separated. Physical activity was 71 
measured by questionnaire and expressed in METhours/week. For analysis, we divided the population in 72 
3 equal groups (tertile).
17
 Alcohol consumption was categorized as less than 1 glass/day, 1-4 glasses/day 73 
for men and 1-2 glasses/day for women, and > 4 glasses/day for men and > 2 glasses/day for women. 74 
Comorbidity was considered present when “non-obesity related cancers other than skin cancer” or 75 
chronic obstructive pulmonary disease was prevalent at baseline. We excluded cancers which are 76 
associated with obesity,
18
 or cancers that are curable and not likely to be related to weight loss or 77 
mortality, such as skin cancer.
19 Chronic obstructive pulmonary disease was defined as a type of 78 
obstructive lung disease characterized by airflow limitation not fully reversible.
20
 Chronic obstructive 79 
pulmonary disease has been shown to be accompanied with weight loss.
21
  80 
Hypertension, dyslipidemia and diabetes mellitus were considered as intermediates and not confounding 81 
variables in the association of obesity with CVD and mortality, therefore, in a sensitivity analysis, we 82 
repeated our analyses by excluding individuals with hypertension, dyslipidemia or diabetes. The presence 83 
of hypertension and dyslipidemia was based on medication information, whereas diabetes mellitus was 84 
defined as the documented use of medication or fasting plasma glucose level ≥ 110 mg/dL. 85 
Assessment of outcome 86 
The main outcome measures under study was incident non-fatal or fatal CVD and overall mortality. In the 87 
Rotterdam Study, CVD is defined as the presence of one or more definite manifestation of coronary heart 88 
disease (coronary revascularization or non-fatal or fatal myocardial infarction or death due to coronary 89 
heart disease), stroke and heart failure. Definite and possible fatal coronary heart disease events are 90 
coded by using the definitions applied within the Cardiovascular Health Study and Atherosclerosis Risk in 91 
the Communities Study.
22
 Stroke is defined as a syndrome of rapidly developing clinical signs of focal (or 92 
global) disturbance of cerebral function, with symptoms lasting 24 h or longer or leading to death, with no 93 
apparent origin other than vascular.
23
 Heart failure was defined using the criteria of the European Society 94 
of Cardiology as a combination of heart failure diagnosed by a medical specialist and the presence of 95 
typical symptoms of heart failure, such as breathlessness at rest or during exertion, ankle edema, and 96 
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pulmonary crepitation, confirmed by objective evidence of cardiac dysfunction (chest X-ray, 97 
echocardiography).
24
 Data on incident CVD is collected using an automated follow-up system, through 98 
gathering information from general practitioners working in the study area. Information about cause and 99 
circumstances of death was obtained from general practitioner medical records and from municipal 100 
records. Research physicians reviewed all available information and coded the events according to the 101 
International Classification of Diseases, 10th edition (ICD-10). A consensus panel, led by a physician with 102 
expertise in field, adjudicated the final cause of death according to ICD-10 codes using standardized 103 
definitions. The follow-up was complete until January 1, 2010.  104 
Statistical analysis 105 
We created population-based multistate life tables to calculate the differences in life expectancy and 106 
years lived with and without CVD in normal weight, overweight and obese groups.
25
 We constructed three 107 
different health states: free of CVD, CVD and death. The possible transition directions were from free of 108 
CVD to CVD, free of CVD to death and from CVD to death. No backflows were allowed (e.g. from CVD to 109 
not having CVD), and only first event into state was considered.  110 
First, we calculated the overall age- and sex-specific rates for each transition with Poisson regression 111 
using the Gompertz distribution to obtain smoothed age- and sex-specific rates. Second, we calculated 112 
the prevalence of normal weight, overweight and obesity by sex, 10-year age groups, and separately for 113 
subjects with and without CVD. Third, we computed gender specific hazard ratios comparing overweight 114 
and obese to normal weight individuals by using Poisson regression with “Gompertz” distribution in 2 115 
models. Model 1 was adjusted for age; and Model 2 was adjusted for age, smoking status, cigarettes 116 
smoked per day (for current smokers), alcohol consumption, education, marital status, physical activity 117 
and comorbidities (“non-obesity related cancers other than skin cancer” or chronic obstructive pulmonary 118 
disease).  119 
Finally, the three sets of transitions rates were calculated for each category of BMI separately using the 120 
(a) overall transition rates, the (b) adjusted hazard ratios (model 2) for CVD and mortality, and the (c) 121 
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prevalence. Similar calculations have been described previously.
26, 27
 The multistate life table started at 122 
age 55 years and closed at age 100 years.  123 
Confidence intervals for all life expectancies and their differences were calculated using @RISK software 124 
(Anonymous 2000; MathSoft Inc, Cambridge, Mass), by Monte Carlo simulation (parametric 125 
bootstrapping) 10 000 runs.
28
 126 
Although we adjusted for smoking and comorbidities, to exclude any potential bias caused by smoking or 127 
comorbidities we repeated the analysis among nonsmokers and individuals without comorbidities (“non-128 
obesity related cancers other than skin cancer” or chronic obstructive pulmonary disease) at baseline 129 
(n=5117). Additionally, we estimated the life expectancy among participants without hypertension, 130 
hyperlipidemia and diabetes mellitus at baseline (n=3750). Also we computed lifetables for individuals 131 
who were older than 65 years at baseline (n=4245). Moreover, we estimated the hazard ratios after 132 
excluding cardiovascular events (n=127) or deaths (n=145) during the first two years of follow-up to take 133 
in account the reverse causation. 134 
To deal with missing values (less than 5%) for covariates including education, marital status, physical 135 
activity, and alcohol we used single imputation with the Expectation Maximization method in SPSS (IBM 136 
SPSS Statistical for Windows, Armonk, New York: IBM Corp). 137 
We used STATA version 13 for Windows (StataCorp, College Station) and R version 3.1.3 (R Foundation 138 
for Statistical Computing, Vienna, Austria) for our analysis.   139 




In total we observed 1035 (18.6%) incident CVD events and 1902 (28.7%) overall deaths over 12 years of 141 
follow-up. Thirty five percent of overall death were from CVD, and 28.5% were from  malignant cancers. 142 
Compared to women, men at baseline were younger and smoked more, showed lower levels of BMI and 143 
physical activity, but higher education levels (Table 1).  144 
Cardiovascular events and death 145 
Table 2 shows the hazard ratios (HR) of the association between categories of BMI with risk of incident 146 
CVD and mortality among men and women. In multivariable adjusted model, obesity (as classified by BMI 147 
higher than 30) was associated with an increased risk of incident CVD among men (HR 1.57 (95% 148 
confidence interval (CI) 1.17, 2.11)) and women (HR 1.49 (95%CI 1.19, 1.86)) compared with normal 149 
weight individuals (Table 2).  150 
Among men and women without CVD, overweight and obesity, compared to normal weight individuals, 151 
were not associated with mortality (Table 2, Model 2).  152 
Among men with CVD, overweight and obesity, compared to normal weight, showed a decreased risk of 153 
mortality (HR (95%CI) 0.81 (0.66, 0.98) and 0.67 (0.49, 0.90), respectively). The association between 154 
overweight and obesity with mortality among women with CVD did not reach a statistical significance.  155 
Total life expectancy and life expectancy with and without CVD 156 
The association between normal weight, overweight and obesity with the risk of each transition (no CVD, 157 
CVD and death) was translated into number of years lived with and without CVD (Figure and Table 3). 158 
Total life expectancy for men and women with overweight and obesity were not significantly different than 159 
normal weight counterparts. Compared to normal weight men, life expectancy of 55-year-old men in the 160 
overweight group was 0.1 (95%CI -0.8, 1.0) years longer, and in the obese group 0.3 years (95%CI -1.1, 161 
1.6). For women, these differences were: 0.6 (95%CI -0.2, 1.3) and -0.2 (-1.2, 0.7) years respectively 162 
(Table 3). For both men and women, obesity was associated with fewer years lived without CVD and 163 
more years lived with CVD than their normal weight counterparts. Men and women with obesity lived 2.6 164 
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(95%CI -4.8, -0.4) and 1.9 (95%CI -3.3, -0.9) fewer years without CVD, respectively, than those in normal 165 
weight group. Additionally, obese men and women lived more years with CVD than their normal weight 166 
counterparts; 2.9 (95%CI 1.1, 4.8) years for men and 1.7 (95%CI 0.6, 2.8) years for women (Figure and 167 
Table 3).  168 
Total life expectancy, number of years lived with and without CVD for normal weight, overweight and 169 
obese for non-smokers and individuals without prevalent comorbidities (“non-obesity related cancers 170 
other than skin cancer” and chronic obstructive pulmonary disease) are presented in Supplementary 171 
Figure 1, and for individuals without hypertension, dyslipidemia and diabetes are presented in 172 
Supplementary Figure 2, and for individuals older than 65 at baseline are presented in Supplementary 173 
Figure 3. As expected, total life expectancy increased for individuals who were nonsmokers and without 174 
comorbidities at baseline, or for individuals without diabetes, hypertension and dyslipidemia, but all 175 
differences among normal weight, overweight and obese individuals were similar to those found in the 176 
total population. However, differences of the BMI categories in total life expectancy and life expectancy 177 
with and without CVD became smaller for individuals older than 65 at baseline. Table 1 in the 178 
Supplementary Material shows the baseline characteristics of individuals who did not visited the research 179 
center or without information of BMI. This subgroup of individuals were older than individuals included in 180 
study, and therefore, were less physically active. Additionally, when we repeated the main analysis after 181 
excluding deaths during first 2 years of follow-up, we found generally similar results (Table 2 in the 182 
Supplementary Material).  183 




Overall we found that compared to normal weight, overweight and obesity in middle age and elderly have 185 
a considerable effect on years lived with and without CVD, although they had no effect on total life 186 
expectancy. Total life expectancy for obese men and women at age 55 years was not significantly 187 
different from the normal weight individuals. However, obesity was associated with 2.6 fewer years lived 188 
without CVD for men and 1.9 years for women. Moreover, men and women with obesity spent an extra of 189 
2.9 and 1.7 years living with CVD, respectively.  190 
The shorter life expectancy without CVD among men and women with obesity was due to increased CVD 191 
and mortality risk. Higher risk for CVD is reflected by an earlier occurrence of CVD over the lifespan and 192 
therefore, a shorter life expectancy without CVD. Furthermore, higher risk of mortality among individuals 193 
without history of CVD follows a decrease in the total life expectancy and consequently, a shorter life 194 
expectancy without CVD could be expected. We also found that compared to normal weight, individuals 195 
with obesity spent more years living with CVD. Years spent  with CVD is a consequence of CVD risk in 196 
those without history of CVD, and mortality risk in those with history of CVD. In our study, obese 197 
individuals without history of CVD had an increased risk for CVD, while obese individuals with history of 198 
CVD had lower risk of mortality. Taken together, this indicate that individuals with obesity will spend more 199 
years living with CVD. 200 
Our analysis indicated that obesity increased the risk of CVD in men and women, and the hazard ratios 201 
were comparable with other studies.
29, 30
 The relation between obesity and mortality is well documented 202 
among younger and middle aged populations.
31
 However, among the late middle aged as well as elderly, 203 
higher BMI has not been consistently associated with higher mortality risk.
3, 5
 Additionally, a previous 204 
meta-analysis by Flegal et al., reported that overweight individuals are at lower risk of mortality, compared 205 
with normal weight individuals.
4
 Our study do not report a protective associations of an increased BMI in 206 
individuals without CVD. However, among overweight and obese men with CVD at baseline, after 207 
adjusting for possible confounders, we found that the risk of mortality decreased by 33% in obese 208 
individuals, compared with normal weight individuals. Although, the role of obesity among the older adults 209 
is still a topic of debate, some studies have suggested that being overweight and obese could serve as a 210 
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nutritional deposit in hardship conditions such as inflammation and disease.
32, 33
 In contrast, some studies 211 
have rejected this paradigm, attributing the lower risk of mortality to the fact that BMI becomes less 212 
sensitive to fat mass and body fat distribution in older individuals.
34
 To reduce the potential effect of 213 
underlying disease, we performed a series of sensitivity analysis in individuals without hypertension, 214 
dyslipidemia and diabetes; in nonsmokers and without comorbidities at baseline. Restricting the analyses 215 
to these subgroups did not generally modify the life expectancies associated with obesity.
 216 
In our study, we found that the effect of overweight and obesity in total life expectancy is minimal. Earlier 217 
studies comprising the participants from the Framingham Heart Study showed larger differences in life 218 
expectancy between obese and normal weight.
9, 11
 Peeters et al., showed that at age of 40 years life 219 
expectancy differences for obese and normal weight men is 5.8 years in nonsmoker and 6.7 in smokers.
9
 220 
Another study by Pardo Silva et al., noted that men with obesity lived 3.3 years and women 6.9 years 221 
shorter from age 45 than those who were normal weight.
11
 Additionally, this study showed that obese 222 
men and women aged 45 years live 6.0 and 8.4 years fewer free of CVD, whereas in our study the 223 
difference was smaller; 2.6 and 1.9 years for men and women, respectively.
11
 The differences between 224 
our findings and those of previous studies from Framingham Heart Study could be explained by two 225 
factors. First, our participants were 10 to 15 years older at baseline, and the association of obesity on 226 
mortality might change with increasing age.
5
 Secondly, the calendar time when the studies were 227 
conducted is different. While the Framingham Heart Study included participants from 1948-1950 and 228 
followed them up during the second half of the 20
th
 century, our study included participants from 1997-229 
2001 with follow up until 2010. There have been reports of progressive improvements in the treatment for 230 
cardiovascular risk factors after 1990, which resulted in the reduction of cardiovascular incidence and 231 
mortality rates.
13
 Our analysis is comparable to the Health and Retirement Survey, a US prospective 232 
longitudinal study.
35
 Similar to ours findings they reported that total life expectancy at age 55 in men and 233 
women was not affected by overweight and obesity. Nevertheless, they did not evaluate the impact of 234 
obesity on life expectancy with and without CVD.
35
 Additionally, our findings on the influence of obesity on 235 
total life expectancy are consistent with earlier analyses within Rotterdam Study by Walter et al., in 2009 236 
(conduced in RS-I, with baseline measures from 1990-1993).
36
 Walter et al., evaluated the impact of 237 
overweight and obesity on disability and mortality by using a different approach from ours to calculate the 238 
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total life expectancy, which took into account the recovery from disability.
36
 However, in line with our 239 
findings Walter et al., concluded that obesity was not associated with a reduction in total life expectancy, 240 
but was associated with a higher risk of becoming and remaining disabled.
36
 In the current analyses we 241 
found that obese individuals tend to have CVD earlier in life and will spend more time living with CVD. 242 
The strengths of our study include availability of a long follow-up time with detailed and validated 243 
information on anthropometrics, CVD and mortality. Anthropometrics such as height and weight were 244 
measured in the research center by trained staff  and do not depend on self-reported information. 245 
Nevertheless, the studies which evaluate the association of obesity with mortality could be prone to 246 
incorrect adjustment for confounders such as smoking or weight loss related to diseases and 247 
comorbidities. In our study, we adjusted for smoking status and the cigarettes smoked per day. Also, we 248 
adjusted and additionally excluded participants that had “non-obesity related cancers other than skin 249 
cancer” or chronic obstructive pulmonary disease. Sensitivity analysis was also performed in individuals 250 
who did not died during the first 2 years of follow-up. We did not adjust for hypertension, dyslipidemia or 251 
diabetes since those factors could be considered intermediates and not confounders. However, we 252 
repeated the analysis among participants without hypertension and diabetes at the baseline. 253 
Our study showed that among late middle age and elderly individuals overweight and obesity do not 254 
seem to have an impact on total life expectancy, but are associated with earlier and extended periods 255 
lived with CVD. The impact of obesity on life expectancy with and without CVD was larger in men than in 256 
women. Due to the increasing prevalence of obesity and the improved treatment of CVD, we might expect 257 
more individuals living with CVD and for a longer period of time. This will result in increasing costs of 258 
healthcare and poorer levels of quality of life.  259 
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Figure. Effect of obesity on life expectancy with and without cardiovascular disease (CVD) at age 55 414 
years.  415 
 416 
Legend figure 417 
Body mass index (BMI) categories: Normal weight BMI is <25kg/m2; Overweight BMI is 25-30kg/m2 and 418 
Obese the BMI is ≥30kg/m2. LE, life expectancy; CVD, cardiovascular disease. 419 
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Table 1. Baseline characteristics of study population. 
Characteristics Men Women 
Population   
    n 2886 (42%) 3750 (58%) 
    Age at interview (years) 68.77.9 69.78.4 
Anthropometry   
   BMI (kg m
-2
) 26.63.2 27.54.4 
      Normal (BMI 18.5-25) 944 (32.7) 1201 (32.0) 
      Overweight (BMI 25-30) 1545 (53.5) 1613 (43.0) 
      Obese (BMI 30+) 397 (13.8) 936 (25.0) 
Social economic status   
   Marital status   
      Single 84 (3.0) 261 (7.0) 
      Married 2284 (79.1) 2008 (53.5) 
      Widowed 310 (10.7) 1099 (29.3) 
      Divorced/separated 208 (7.2) 382 (10.2) 
   Education   
      Elementary 274 (9.5) 632 (16.6) 
      Lower secondary 870 (30.1) 2003 (53.4) 
      Higher secondary 1122 (38.9) 879 (23.4) 
      Tertiary 620 (21.5) 245 (6.6) 
Lifestyle variables   
   Smoking   
      Never smoking 759 (26.2) 2303 (61.4) 
      Former smoker 1654 (57.3) 1104 (29.4) 
      Current smoker 473 (16.3) 343 (9.1) 
      Daily cigarettes smoked 2.87.0 2.36.1 
   Alcohol (drinks/day)   
     < 1 glass/day 1289 (44.7) 2674 (71.3) 
    1-4 glasses/day (men); 1-2 glasses/day (women) 1363 (47.2) 669 (17.8) 
    > 4 glasses/day (men); > 2 glasses/day (women) 234 (8.1) 407 (10.9) 
   Physical activity (METh) 73.843.9 92.143.3 
  Treatment for hypertension 641 (22.2) 997 (26.2) 
  Treatment for dyslipidemia 415 (14.4) 473 (12.6) 
  Diabetes mellitus 338 (15.1) 438 (11.7) 
  Comorbidities (cancer† and chronic obstructive pulmonary disease) 274 (9.5) 216 (5.8) 
Values are means (SDs) or numbers (percentages). BMI, body mass index. 
†Cancer includes “non-obesity related cancers other than skin cancer” 
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Table 2. Hazard ratios for Cardiovascular disease (CVD) and Death for overweight and obese men and women. 
   Men  Women  
Transition  Categories 
Model 1 HR 
(95% CI)† 
Model 2 HR 
(95% CI) ‡ 
Model 1 HR 
(95% CI)† 
Model 2 HR 
(95% CI) ‡ 
Incident CVD  Normal weight 1.0 1.0 1.0 1.0 
  Overweight 1.17 (0.95, 1.44) 1.19 (0.96, 1.47) 1.17 (0.95, 1.43) 1.20 (0.98, 1.47) 
  Obese 1.56 (1.17, 2.09) 1.57 (1.17, 2.11) 1.47 (1.18, 1.83) 1.49 (1.19, 1.86) 
       
Mortality among those without CVD  Normal weight 1.0 1.0 1.0 1.0 
  Overweight 1.02 (0.85, 1.20) 1.06 (0.89, 1.27) 0.83 (0.70, 0.99) 0.86 (0.72, 1.03) 
  Obese 1.03 (0.78, 1.36) 1.08 (0.81, 1.43) 1.01 (0.83, 1.22) 1.02 (0.83, 1.24) 
       
Mortality among those with CVD  Normal weight 1.0 1.0 1.0 1.0 
  Overweight 0.78 (0.65, 0.94) 0.81 (0.66, 0.98) 0.84 (0.66, 1.05) 0.92 (0.72, 1.16) 
  Obese 0.64 (0.47, 0.86) 0.67 (0.49, 0.90) 0.76 (0.59, 0.98) 0.84 (0.64, 1.09) 
 
†Adjusted for age. 
‡Adjusted for age, smoking, cigarettes smoked per day, education level, marital status, physical activity, alcohol use and comorbidities (“non-
obesity related cancers other than skin cancer” or chronic obstructive pulmonary disease). 
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Table 3. Differences in life expectancy, in years, at age 55 for normal weight, overweight and obesity in men and women 
 Total LE 
Differences in 
total LE 
LE free of CVD 
Differences in 
number of years 
lived free of CVD 
LE with CVD 
Differences in 
number of years 
lived with CVD 
Body mass index 
   Men       
      Normal weight 26.5 (26.0, 27.1) Ref 22.3 (21.6, 23.0) Ref 4.2 (3.8, 4.7) Ref 
      Overweight 26.6 (26.1, 27.2) 0.1 (-0.8, 1.0) 21.3 (20.7, 22.0) -1.0 (-2.1, 0.2) 5.3 (4.8, 5.8) 1.1 (0.3, 1.9) 
      Obese 26.8 (25.5, 28.1) 0.3 (-1.1, 1.6) 19.7 (17.7, 21.7) -2.6 (-4.8, -0.4) 7.1 (5.4, 8.9) 2.9 (1.1, 4.8) 
   Women       
      Normal weight 30.8 (30.3, 31.3) Ref 27.1 (26.5, 27.7) Ref 3.7 (3.2, 4.1) Ref 
      Overweight 31.3 (30.7, 32.0) 0.6 (-0.2, 1.3) 26.8 (26.0, 27.6) -0.3 (-1.3, 0.7) 4.5 (3.9, 5.2) 0.9 (0.1, 1.6) 
      Obese 30.7 (30.0, 31.5) -0.2 (-1.2, 0.7) 25.2 (24.1, 26.1) -1.9 (-3.3, -0.9) 5.3 (4.4, 6.3) 1.7 (0.6, 2.8) 
LE, life expectancy; CVD, cardiovascular disease 
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